CDK2 and prostate cancer: Correlation analyses also indicated that CDK4 expression was positively correlated with expressions of CDK2 and CDK6 in liver cancer, lung cancer, prostate cancer, pancreatic cancer, melanoma, head and neck cancer, glioblastoma, breast cancer, and cervical cancer cohorts (r = 0.06~0.69).